Cisen Pharmaceutical Co Ltd (603367) - Total Liabilities
Based on the latest financial reports, Cisen Pharmaceutical Co Ltd (603367) has total liabilities worth CN¥1.43 Billion CNY (≈ $208.78 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 603367 cash flow conversion to assess how effectively this company generates cash.
Cisen Pharmaceutical Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Cisen Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Cisen Pharmaceutical Co Ltd (603367) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Cisen Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Cisen Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Episil-Precision Inc
TW:3016
|
Taiwan | NT$1.83 Billion |
|
Chengdu Guibao Science Tech
SHE:300019
|
China | CN¥1.39 Billion |
|
Jiangsu LiXing General Steel Ball Co Ltd
SHE:300421
|
China | CN¥697.50 Million |
|
Altareit
PA:AREIT
|
France | €2.67 Billion |
|
JC Finance & Tax Interconnect Holdings Ltd
SHE:002530
|
China | CN¥760.85 Million |
|
ARB Corporation Ltd
AU:ARB
|
Australia | AU$134.90 Million |
|
Helix Energy Solutions Group Inc
NYSE:HLX
|
USA | $1.06 Billion |
|
CTCI Corp
TW:9933
|
Taiwan | NT$114.47 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Cisen Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cisen Pharmaceutical Co Ltd (603367) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cisen Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cisen Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total liabilities of Cisen Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.57 Billion ≈ $229.28 Million |
-0.29% |
| 2023-12-31 | CN¥1.57 Billion ≈ $229.94 Million |
+7.68% |
| 2022-12-31 | CN¥1.46 Billion ≈ $213.53 Million |
+11.55% |
| 2021-12-31 | CN¥1.31 Billion ≈ $191.42 Million |
-4.08% |
| 2020-12-31 | CN¥1.36 Billion ≈ $199.56 Million |
+42.06% |
| 2019-12-31 | CN¥959.97 Million ≈ $140.47 Million |
-12.20% |
| 2018-12-31 | CN¥1.09 Billion ≈ $160.00 Million |
+7.45% |
| 2017-12-31 | CN¥1.02 Billion ≈ $148.91 Million |
+3.60% |
| 2016-12-31 | CN¥982.26 Million ≈ $143.74 Million |
+5.02% |
| 2015-12-31 | CN¥935.33 Million ≈ $136.87 Million |
+18.03% |
| 2014-12-31 | CN¥792.44 Million ≈ $115.96 Million |
+24.50% |
| 2013-12-31 | CN¥636.48 Million ≈ $93.14 Million |
+35.40% |
| 2012-12-31 | CN¥470.06 Million ≈ $68.79 Million |
+104.36% |
| 2011-12-31 | CN¥230.02 Million ≈ $33.66 Million |
-- |
About Cisen Pharmaceutical Co Ltd
Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products in China and internationally. The company's chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infe… Read more